
Lisata Therapeutics Sets 1-for-15 Reverse Stock Split, Effective Nov. 23
Split-adjusted trading begins Nov. 23 under the existing LSTA ticker, with a new CUSIP of 128058 401.
Lisata Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations

Split-adjusted trading begins Nov. 23 under the existing LSTA ticker, with a new CUSIP of 128058 401.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Financial statements and exhibits
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits
AI summary, unreviewedLisata Therapeutics announces one-for-fifteen reverse stock split effective November 23, 2026, cutting shares outstanding from about 10.8 million to about 0.7 million
Financial statements and exhibits
Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Other events · Financial statements and exhibits
AI summary, unreviewedLisata Therapeutics Annual Meeting Approves 2026 Equity Plan and Reverse Split Authority, But Series C Conversion Proposal Adjourned to November 30
Departure/appointment of directors or officers · Financial statements and exhibits
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Departure/appointment of directors or officers · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits